CoChat

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

Tang, An, Rabasa-Lhoret, Rémi, Castel, Hélène, Wartelle-Bladou, Claire, Gilbert, Guillaume, Massicotte-Tisluck, Karine, Chartrand, Gabriel, Olivié, Damien, Julien, Anne-Sophie, de Guise, Jacques, Soulez, Gilles, Chiasson, Jean-Louis · 2015 · Diabetes Care
Cited by 133

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This study determined the effects of insulin versus liraglutide therapy on liver fat in patients with type 2 diabetes inadequately controlled with oral agents therapy, including metformin. RESEARCH DESIGN AND METHODS: Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks. The liver proton density fat fraction (PDFF) was measured by MRS. The mean liver PDFF, the total liver volume, and the total liver fat index were measured by MRI. The Student t test, the Fisher exact test, and repeated-measures ANOVA were used for statistical analysis. RESULTS: Insulin treatment was associated with a significant improvement in glycated hemoglobin (7.9% to 7.2% [62.5 to 55.2 mmol/mol], P = 0.005), a trend toward a decrease in MRS-PDFF (12.6% to 9.9%, P = 0.06), and a significant decrease in liver mean MRI-PDFF (13.8% to 10.6%, P = 0.005), liver volume (2,010.6 to 1,858.7 mL, P = 0.01), and the total liver fat index (304.4 vs. 209.3 % ⋅ mL, P = 0.01). Liraglutide treatment was also associated with a significant improvement in glycated hemoglobin (7.6% to 6.7% [59.8 to 50.2 mmol/mol], P < 0.001) but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39). CONCLUSIONS: The administration of insulin glargine therapy reduced the liver fat burden in patients with type 2 diabetes. However, the improvements in the liver fat fraction and glycemia control were not significantly different from those in the liraglutide group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc14-2548

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. Wallia, 2014, Insulin therapy for type 2 diabetes mellitus, JAMA, 311, 2315, 10.1001/jama.2014.5951 · DOI · Paper page
  2. Tilg, 2008, Insulin resistance, inflammation, and non-alcoholic fatty liver disease, Trends Endocrinol Metab, 19, 371, 10.1016/j.tem.2008.08.005 · DOI · Paper page
  3. Lingvay, 2007, Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes, J Diabetes Complications, 21, 137, 10.1016/j.jdiacomp.2007.02.005 · DOI
  4. Jankovic, 2012, Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus, PLoS ONE, 7, e50077, 10.1371/journal.pone.0050077 · DOI
  5. Shah, 2011, Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes, Diabetes Obes Metab, 13, 505, 10.1111/j.1463-1326.2011.01370.x · DOI · Paper page
  6. Mells, 2012, Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet, Am J Physiol Gastrointest Liver Physiol, 302, G225, 10.1152/ajpgi.00274.2011 · DOI · Paper page
  7. Ben-Shlomo, 2011, Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase, J Hepatol, 54, 1214, 10.1016/j.jhep.2010.09.032 · DOI · Paper page
  8. Reeder, 2011, Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy, J Magn Reson Imaging, 34, 729, 10.1002/jmri.22580 · DOI · Paper page
  9. Tang, 2013, Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis, Radiology, 267, 422, 10.1148/radiol.12120896 · DOI · Paper page
  10. Anderwald, 2002, Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle, Diabetes, 51, 3025, 10.2337/diabetes.51.10.3025 · DOI · Paper page
  11. Vanhamme, 1997, Improved method for accurate and efficient quantification of MRS data with use of prior knowledge, J Magn Reson, 129, 35, 10.1006/jmre.1997.1244 · DOI · Paper page
  12. Hamilton, 2011, In vivo characterization of the liver fat ¹H MR spectrum, NMR Biomed, 24, 784, 10.1002/nbm.1622 · DOI · Paper page
  13. Yokoo, 2011, Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T, Radiology, 258, 749, 10.1148/radiol.10100659 · DOI · Paper page
  14. Tang, 2014, Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis, Abdom Imaging
  15. Nomura, 1987, Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet, Radiology, 162, 845, 10.1148/radiology.162.3.3809503 · DOI
  16. Chen, 2008, Correlation between hepatic steatosis, hepatic volume, and spleen volume in live liver donors, Transplant Proc, 40, 2481, 10.1016/j.transproceed.2008.08.045 · DOI
  17. Shirakawa, 2012, Effects of liraglutide on β-cell-specific glucokinase-deficient neonatal mice, Endocrinology, 153, 3066, 10.1210/en.2012-1165 · DOI
  18. Suzuki, 2013, Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus, Intern Med, 52, 1029, 10.2169/internalmedicine.52.8961 · DOI · Paper page
  19. Jonker, 2013, Exercise and type 2 diabetes mellitus: changes in tissue-specific fat distribution and cardiac function, Radiology, 269, 434, 10.1148/radiol.13121631 · DOI · Paper page
  20. Chaudhuri, 2012, Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis, Diabetes Metab Res Rev, 28, 258, 10.1002/dmrr.1305 · DOI
  21. Fernández-Salazar, 2011, Percutaneous liver biopsy: patients’ point of view, Scand J Gastroenterol, 46, 727, 10.3109/00365521.2011.558112 · DOI

Cited by

See all 133

Metadata

Authors
Tang, A., Rabasa-Lhoret, R., Castel, H., Wartelle-Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A.-S., de Guise, J., Soulez, G., & Chiasson, J.-L.
Venue
Diabetes Care
Published
2015-03-26
Volume
38
Issue
7
Pages
1339-1346
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2087484038
Cited by
133
References
13
FWCI
9.40
Type
journal article
Language
en
Open access
closed
Funders
  • Diabète Québec
  • Canadian Heads of Academic Radiology-GE Healthcare
  • NSERC Discovery (107998)
  • Fonds de recherche du Québec en Santé (FRQ-S) and Fondation de l'association des radiologistes du Québec. Clinical Research Scholarship to An Tang (#26993)
  • J-A DeSève Research Chair to Rémi Rabasa-Lhoret
  • FRQ-S National Scientist Award to Gilles Soulez
  • FRQ-S Senior Scholarship to Rémi Rabasa-Lhoret
  • Canada Research Chair in 3D imaging and Biomedical Engineering to Jacques de Guise
  • Radiological Society of North America Research and Education Foundation (RSD1108)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.